Navigation Links
Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
Date:4/20/2012

EAST BRUNSWICK, N.J., April 20, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company's first quarter financial results will be released prior to the open of the market on Wednesday, May 9, 2012.
Savient executive management will host a conference call beginning at 9:00 a.m. Eastern Time on May 9, 2012, to discuss these results and to answer questions.

To participate by telephone, please dial 866-393-1565 (Domestic) or 253-237-1151 (International). The conference ID number is 72346185.  The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com.  A telephone replay will be available from 12:00 p.m. Eastern Time on May 9, 2012, through 12:00 a.m. Eastern Time on May 16, 2012, by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering conference ID number 72346185.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT-IContact: Mary Coleman

Carney Noensie Savient Pharmaceuticals, Inc.

Burns McClellan information@savient.com

cnoensie@burnsmc.com (732) 418-9300

(212) 213-0006


'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Imperial Capital Healthcare Investor Forum
2. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results
3. Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
4. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
5. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
6. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
7. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
8. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
9. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
10. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
11. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2019)... (PRWEB) , ... September 22, 2019 , ... ... Bellevue, WA offering the highest level of both plastic surgery and non-surgical aesthetic ... FDA-cleared microneedling device. Microneedling is a proven skin rejuvenation treatment that uses tiny ...
(Date:9/18/2019)... WASHINGTON, Pa. (PRWEB) , ... ... ... Inc. (USH), parent organization to ReachMD, Global Learning Collaborative, and other healthcare-focused ... digital learning environment, DecisionSim™, uses real-world cases to challenge healthcare professionals (HCPs) ...
(Date:9/17/2019)... (PRWEB) , ... September 18, 2019 , ... Uniform ... Beyond Breast Cancer to raise funds for Breast Cancer programs and services. , This ... 42,000 will die of the disease. During the month of October 2019, Uniform Advantage ...
Breaking Medicine Technology:
(Date:9/18/2019)... ... , ... A new study by BestPlaces looks at ten indicators to produce the first ranking ... so other related rights vary widely across the 50 states. , Ten topics ... orientation) , Employment , Education , Gender Marker Updates ...
(Date:9/17/2019)... ... 17, 2019 , ... Since the registration of the NociScan ... in the US, Nocimed has been marketing its unique technology to healthcare clinicians ... MRI equipment to perform MR spectroscopy, NociScan detects the presence of chemical biomarkers ...
(Date:9/17/2019)... N.Y. (PRWEB) , ... September 17, 2019 , ... ... medicine cabinet could help extend the lives of some cancer patients? In companion ... Chicago, doctors from Roswell Park Comprehensive Cancer Center report new evidence that low-dose ...
(Date:9/17/2019)... ... 17, 2019 , ... The Center for Information and Study ... third edition of The Gift of Participation. Written by CISCRP Founder, Ken Getz, ... navigate the clinical research process. The new edition offers a fresh look at ...
(Date:9/12/2019)... (PRWEB) , ... September 12, 2019 , ... ... both a local and national scale in two recent and well-renowned listing publications, ... fastest-growing privately held businesses for the 2019 year. , Dr. Jeffrey Donaldson, ...
Breaking Medicine News(10 mins):